Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
NORCROSS, Ga., Aug. 14, 2013 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the second quarter and first six months ended June 30, 2013. These results are included in the Company’s Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission.
Help employers find you! Check out all the jobs and post your resume.
